Inhibrx is a clinical-stage biotechnology company that focuses on developing innovative therapeutic candidates for life-threatening conditions. The company leverages its expertise in protein engineering and a proprietary single-domain antibody platform to create a diverse pipeline of biologic therapeutics. Their approach emphasizes the development of multivalent candidates that are engineered to optimize receptor clustering, which enhances their therapeutic efficacy. Notable candidates in their pipeline include Ozekibart (INBRX-109), a tetravalent DR5 agonist designed to induce tumor-selective programmed cell death, and INBRX-106, a hexavalent OX40 agonist aimed at promoting T-cell expansion and enhancing immune response in patients with advanced solid tumors.

Inhibrx's scientific strategy is characterized by an agile and innovative mindset, allowing the company to build upon established discoveries in biotherapeutics. Their team comprises experienced professionals with deep scientific and clinical backgrounds, enabling them to navigate the complexities of drug development effectively. The company is committed to advancing its pipeline through rigorous research and development, with a focus on creating therapies that demonstrate superior mechanisms of action compared to existing treatments in the field.

United States

Inhibrx is a clinical-stage biotechnology company dedicated to helping people with life-threatening conditions through scientific innovation and excellence. They have a pipeline of novel biologic therapeutic candidates developed using their protein engineering expertise.

Cancer

Genetic Diseases

Liver Diseases

Lung Diseases

Inhibrx

Severe alpha-1 antitrypsin deficiency

INBRX-101

Antibodies

Biologics

Chondrosarcoma

Solid tumor/s

INBRX-109 is a precisely engineered tetravalent sdAb-based therapeutic candidate currently being evaluated in patients diagnosed with chondrosarcoma, mesothelioma, pancreatic adenocarcinoma, gastric adenocarcinoma, and synovial sarcoma. INBRX-109 agonizes DR5 to induce tumor selective programmed cell death.

Ozekibart (INBRX-109) (DR5 agonist)

Head and neck squamous cell carcinoma

INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40 currently being evaluated in patients with locally advanced or metastatic solid tumors. Signaling through OX40 provides co-stimulation that promotes T-cell expansion, enhanced effector function and memory cell formation, and prevents activation-induced cell death.
<a href="https://inhibrx.com/inbrx-106/"> 
&nbsp;</a>

INBRX-106 (OX40 agonist) + Keytruda 

Relapsed/refractory Ewing sarcoma

Colorectal cancer

Metastatic colorectal cancer

Ozekibart (INBRX-109) + FOLFIRI

Non-small cell lung carcinoma

INBRX-106

INBRX-105 is a tetravalent sdAb-based therapeutic candidate currently being evaluated in patients with programmed death ligand 1 (PD-L1) expressing tumors, including those refractory to, or relapsed from, approved checkpoint inhibitor therapies. INBRX-105 acts both as an antagonist of PD-L1 and a conditional agonist of 4-1BB.

INBRX-105 (PDL1 X 4-1BB tetravalent conditional agonist) +/- Keytruda 

California - South

California

Therapeutic

Inhibrx

Company Details